Akèy › Gliyoblastòm › Illinois › Chicago
Etid klinik pou Gliyoblastòm nan Chicago, IL
15 etid pou Gliyoblastòm ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Ap rekriteFaz 1/2
- University of Chicago Comprehensive Cancer Center, Chicago
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Ap rekriteFaz 3
- Northwestern University, Chicago
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Ap rekriteFaz 1
- Northwestern Univerity, Chicago
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Ap rekriteFaz 1/2
- Northwestern Memorial Hospital, Chicago
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Ap rekriteFaz 1
- Northwestern University, Chicago
Targeted Pediatric High-Grade Glioma Therapy
Ap rekriteEtid obsèvasyon
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Ap rekriteFaz 1
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Study of Olutasidenib and Temozolomide in HGG
Ap rekriteFaz 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- University of Chicago, Chicago
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Ap rekriteFaz 1
- Northwestern Medicine, Chicago
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Ap rekriteFaz 2
- Northwestern University, Chicago
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Ap rekriteFaz 1 bonèVolontè an sante akeyi
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ap rekriteFaz 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Etid Gliyoblastòm nan lòt vil
- New York City, NY30 etid
- Boston, MA28 etid
- Houston, TX25 etid
- Los Angeles, CA23 etid
- Durham, NC20 etid
- San Francisco, CA17 etid
- Washington, DC15 etid
- Rochester, MN15 etid
- Miami, FL14 etid
- Columbus, OH14 etid
- Jacksonville, FL13 etid
- Aurora, CO12 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.